The association between XRCC1 Arg399Gln polymorphism and endometrial cancer risk: a system review and meta-analysis

Background: The results of the association between XRCC1 Arg399Gln polymorphism and endometrial cancer are inconsistent. The aim of this study is to quantitatively evaluate the relationship between XRCC1 polymorphism and endometrial cancer risk. Methods: Medline, Embase, China National Knowledge Infrastructure and Chinese Biomedicine Databases were searched to identify eligible studies. Summary odds ratios (ORs) and 95% confidence intervals (CIs) for XRCC1 Arg399Gln polymorphism and endometrial cancer were calculated in a fixed-effects model and a random effects model when appropriate. Results: A total of 6 studies (1113 cases and 1226 controls) were enrolled in this meta-analysis. Overall, no significant association was found in pooled analysis. When excluding low-quality studies, significant associations were found among Caucasian population in all model: allele contrast (Arg vs. Gln), OR = 1.58, 95% CI = 1.25-2.00; homozygote (Arg/Arg vs. Gln /Gln), OR = 2.54, 95% CI = 1.56-4.14; heterozygote (Arg/Gln vs. Gln/Gln), OR = 1.46, 95% CI = 1.03-2.07; dominant model (Arg/Arg + Arg/Gln vs. Gln/Gln), OR = 1.69, 95% CI = 1.22-2.35; recessive model (Arg/Arg vs. Arg/Gln + Gln/Gln), OR = 1.91, 95% CI = 1.24-2.96. Conclusion: The XRCC1 Arg399Gln polymorphism may be a risk factor for endometrial cancer in Caucasians.